Abstract Sn (tin4+)-protoporphyrin, a potent competitive inhibitor of haeme oxygenase, the rate limiting enzyme in the degradation of haeme to bile pigments, was given intravenously to six patients with primary biliary cirrhosis and to four patients with idiopathic haemochromatosis. Serum bilirubin concentrations decreased in all patients after administration of 1-2 tmollkg body weight of the metailoporphyrin, given in two doses eight to 24 hours apart. This reduction lasted approximately four to five days after injection of the compound. Excretion of endogenous haeme in bile increased (mean increase approximately two to threefold) in paraliel with the decrease in serum bilirubin concentrations in both patient groups, and the highest biliary haeme concentrations were found during the first 48 hours after treatment. Sn-protoporphyrin was cleared rapidly from plasma with a half-life of 3-4 hours. Biliary bilirubin concentrations decreased (mean decrease,
serum bilirubin concentrations in both patient groups, and the highest biliary haeme concentrations were found during the first 48 hours after treatment. Sn-protoporphyrin was cleared rapidly from plasma with a half-life of 3-4 hours. Biliary bilirubin concentrations decreased (mean decrease, 49%) in the haemochromatosis patients after Snprotoporphyrin administration. No decrease in biliary bilirubin concentrations could be detected in the primary biliary cirrhosis patients under the same conditions. Thus, Snprotoporphyrin treatment resulted in a decrease in serum bilirubin concentrations and an increase in biliary haeme excretion in patients with haemochromatosis and primary biliary cirrhosis, as has previously been shown in normal subjects. The results indicate that the synthetic haeme analogue inhibits haeme oxidation activity in the two patient groups studied, as it does in normal people and in experimental animals. The lack of effect of Snprotoporphyrin on biliary bilirubin excretion in primary biliary cirrhosis may be related to a differently affected hepatic clearance system or to a different distribution of tissue bilirubin pools in this condition.
Sn-protoporphyrin is a potent competitive inhibitor of haeme oxygenase,A1 the rate limiting enzyme in the degradation of haeme to bile pigments.5 The ability of this compound to suppress neonatal jaundice as well as several forms of naturally occurring and experimentally induced jaundice in animals has been extensively documented.II211 It has also been found that administration of the synthetic metalloporphyrin increases the excretion of biliary haeme in animals.12 All of these properties are of potential clinical interest and have stimulated further studies on the effects of Sn-protoporphyrin in humans. We recently showed that Snprotoporphyrin caused a significant decrease in serum bilirubin as well as biliary bilirubin concentrations in healthy normal subjects."3 In addition, the metalloporphyrin was found to inhibit human liver microsomal haeme oxygenase activity in vitro and to enhance biliary haeme excretion. 3 Thus, these results extend our earlier findings in experimental animals'"'2 to normal healthy humans and establish clearly that Sn-protoporphyrin inhibits the rate of haeme degradation to bile pigments in man.
Initial studies in patients with jaundice caused by liver dysfunction or immaturity in hepatic bilirubin conjugating activity have shown that Sn-protoporphyrin can diminish the rate of increase in plasma bilirubin concentrations in term infants with neonatal jaundice associated with ABO-incompatibility, patients with Gilbert's syndrome, and in some patients with primary biliary cirrhosis. 4'5 By using Snprotoporphyrin to inhibit haeme oxygenase activity in vivo we have also defined the existence ofa physiological mechanism for biliary excretion of endogenous undegraded haeme in humans." The effects of inhibition of haeme oxidation activity on biliary bilirubin concentrations have not, however, been characterised previously in patients with hepatic dysfunction.
Patients with idiopathic haemochromatosis have enhanced accumulation ofhepatic iron leading to cirrhosis and increased frequency of liver malignancy.'6 It would therefore be of interest if the excretion of haeme, and consequently the central iron atom of haeme, from the liver could be enhanced by giving Sn-protoporphyrin to these patients. In the present report, therefore, we have carried out studies in patients with primary biliary cirrhosis and idiopathic haemochromatosis and investigated the effects of Sn-protoporphyrin in these subjects.
Materials and methods

SUBJECTS
Six patients with primary biliary cirrhosis (five women and one man) and four patients with All patients were in a metabolic ward in hospital during the study and were kept on a standardised diet.'3 Before Sn-protoporphyrin treatment they were subjected to ultraviolet light testing and this procedure was repeated at the end of the study. As reported elsewhere, ultraviolet light threshold values decreased immediately after administration of the metalloporphyrin'52' but these values quickly reverted to normal in all patients after the end of the studies. Before the study the patients underwent an extensive series of clinical and biochemical tests which were repeated after the study. On both occasions only the parameters associated with the diseases deviated from normal. None of the patients were under medication for their respective diseases during the study. The study was approved by the Ethical Committee of Karolinska Institute, Huddinge University Hospital, the Clinical Trial Department of the Swedish Drug Agency (Socialstyrelsens Lakemedelsavdelning), and the Rockefeller University Institutional Review Board. Informed consent was obtained from all participants.
DESIGN OF THE STUDY
The protocol was designed as a two week study requiring serum as well as bile sampling; it has been described in detail previously."3 Briefly, fasting blood samples were drawn each morning, and in most cases additional blood samples were drawn at 4 pm each day. In some cases, more frequent blood samples were drawn in connection with administration of the metalloporphyrin. The bile sampling procedure was carried out exactly as outlined earlier.'3 One of the patients (patient 6) was, however, unable to complete this procedure. Sn-protoporphyrin was prepared and administered under previously described conditions,'5 and was infused intravenously at a dose of 0-5-1 0 [tmol/kg body weight after which the patients were fed. A second identical infusion was administered eight to 24 hours later.
METHODS
The serum and biliary bilirubin concentrations were assayed by a similar procedure.22 For analysis of biliary lipid composition, a 1 0 ml bile SnPP= Sn-protoporphyrin and the time period before drug treatment (Pre-SnPP) was 3 days while the period after administration of the metalloporphyrin was 4 days. The decrease was rapid in onset and lasted for four to five days (Fig 1) . Thereafter the bilirubin concentrations returned to values before treatment. The effect of Sn-protoporphyrin on serum bile pigment values was in general similar in both groups of patients to those previously reported in healthy volunteers.
II EFFECT ON SN-PROTOPORPHYRIN ON BILIARY BILIRUBIN CONCENTRATIONS
Biliary bilirubin concentrations were measured both before and after Sn-protoporphyrin administration. The basal biliary bilirubin concentration found under these conditions was similar in both patient groups and did not differ from that in healthy controls (Table III) . As is evident from Figure 2 , there was no net reduction in biliary bilirubin concentrations after metalloporphyrin treatment in the patient group with primary biliary cirrhosis. In the patients with haemochromatosis there was a decrease in biliary bilirubin output after Sn-protoporphyrin administration, in agreement with our previous findings in normal humans. The mean decrease in biliary bilirubin in the haemochromatosis group was 49% (p<0005, Student's t-test). No changes were found in the phospholipid and cholesterol content in the bile during the course of the study in either patient group (Table IV) . The values were in close agreement with those for healthy humans.'3 PHARMACOKINETIC STUDIES OF SN-PROTOPORPHYRIN Sn-protoporphyrin was given to each patient in two identical intravenous infusions. The plasma values of Sn-protoporphyrin were measured after the first infusion in three of the patients to determine plasma half life. The initial peak concentration of the metalloporphyrin was = 5 nmol/ml and the decline was log-linear with time with a plasma half life of 3-4 hours, in excellent agreement with the previous findings for healthy volunteers.'3 All patients tolerated the drug well and apart from transient photosensitising effects no side effects were noted.
INFLUENCE OF SN-PROTOPORPHYRIN ON HAEME VALUES IN BILE
In three of the patients with haemochromatosis and in some with primary biliary cirrhosis there were detectable amounts of haeme in the bile before metalloporphyrin treatment (Table V) . The values in the haemochromatosis group were, however, slightly higher than those in the primary biliary cirrhosis group and those previously reported for normal subjects.' After administration of Sn-protoporphyrin, biliary haeme values increased in all four patients with haemochromatosis and in the five subjects with primary biliary cirrhosis. As seen in Table V , the mean increase was found to be approximately threefold. In one of the subjects, patient 7, biliary haeme concentrations were very high (=49-58 Rmol/l) throughout the study and did not change after Sn-protoporphyrin treatment. In addition to cirrhosis of the liver, this patient suffered from haemolytic anaemia and had an enlarged spleen. Thus, the clinical findings of accelerated haemoglobin breakdown in this patient correlated well with the increased biliary excretion of haeme. In all other patients the highest haeme concentrations were found during the first 48 hours after Sn-protoporphyrin The numbers represent mean values from biliary samples taken either before (Pre-SnPP) or after (Post-SnPP) administration of Sn-protoporphyrin (SnPP). The variation between day to day samples in each patient was in general substantial and the numbers given represent mean daily values for each period. The sampling period before drug treatment was in general 3 days, while the period after administration of the metalloporphyrin was 4 days. In three of the patients (2, 4, and 11), no haeme could be detected in the bile samples before the treatment, and it was thus not possible to calculate the relative increase in biliary haeme values which is indicated by the asterisk.' Patient 7 suffered from haemolytic anaemia in addition to cirrhosis of the liver and was therefore excluded when calculating mean values. ND= not detectable. The detection limit of haeme in the assay procedure used was 0 5 tsmolll.
administration. Apart from a somewhat delayed peak in haeme excretion, the pattern correlated well with that found in normal humans. 13
Discussion
We have examined the effect of Snprotoporphyrin administration in patients with primary biliary cirrhosis and idiopathic haemochromatosis on various parameters of haeme and bile pigment metabolism. There is currently no established cure for primary biliary cirrhosis nor has its aetiology been clarified. '8 In advanced stages of the disease, serum bilirubin concentrations increase substantially; the patients reported here were mostly in the early stages of the disease and serum bilirubin concentrations were therefore increased to an abnormal level in only one (Table I) . Serum bilirubin concentrations, however, decreased promptly in all patients after Snprotoporphyrin administration. The effect was seen within 24 hours in all subjects, the mean decrease for the group being 20% (range 14-51%). This value was somewhat less than the corresponding decrease observed for the haemochromatosis patients (32%) and for a control group (38%).'3 The actual decrease in serum bilirubin was, however, similar in all groups (3) (4) [tmol/l), and the smaller relative decrease in the primary biliary cirrhosis group probably reflected a higher baseline bilirubin concentration in these patients. The In contrast to the findings for serum bilirubin, the effect of Sn-protoporphyrin on biliary bilirubin concentrations differed between the two patient groups. In the haemochromatosis patients we were able to show a decrease in biliary bilirubin after Sn-protoporphyrin administration, and this response was similar to that in normal subjects.'3 In the primary biliary cirrhosis patients, however, no such decrease was detected (Fig 2) . There was a considerable interindividual variation in this patient group, but not even when the individual response to Sn-protoporphyrin on biliary bilirubin concentrations was studied were we able to detect a common pattern (Table III) .
Although indirect measurements of hepatic function -such as prothrombin time and serum albumin -were not abnormal in the patients with primary biliary cirrhosis (Table I) , it should be noted that albumin concentrations tended to be lower and bilirubin concentrations tended to be higher in this group than in the patients with haemochromatosis. Even if we consider the possibility unlikely, we cannot at present exclude the presence of a difference in liver function between the two groups.
The absence of a reduction in biliary bilirubin concentrations after Sn-protoporphyrin administration in patients with primary biliary cirrhosis could result from several different factors, including differences in clearance of the metalloporphyrin, differences in the interaction of Snprotoporphyrin with haeme oxygenase in this disorder, variations in the tissue stores of bilirubin, or a decrease in overall bile or bile acid output. We did not find supportive evidence for any of these explanations as the clearance of Snprotoporphyrin was similar in all subjects, serum bilirubin concentrations decreased in the primary biliary cirrhosis group as it did in the haemochromatosis patients, and no reductions in other biliary compounds such as cholesterol, phospholipids, or haeme were detected. Thus, the clear difference in effect on serum and biliary bilirubin concentrations of Sn-protoporphyrin in the primary biliary cirrhosis group compared with normal subjects and patients with haemochromatosis suggests that the hepatic clearance system for bilirubin may be affected differently in the primary biliary cirrhosis patients compared with the other groups investigated, or that patients with primary biliary cirrhosis have a larger pool of tissue bilirubin which masks an effect of metalloporphyrin on biliary bilirubin output. In this circumstance the prompt reduction in the production of bilirubin induced by Sn-protoporphyrin would presumably take longer to affect the tissue pool, and thus the initial output of biliary bilirubin would be unchanged. Under prolonged inhibition of haeme oxidation activity, however, biliary bilirubin concentrations might be expected to be altered in primary biliary cirrhosis patients. Further studies are needed to explore the longterm effects of Sn-protoporphyrin treatment on bile pigment disposal in this patient group.
The second clinical group we studied were patients with idiopathic haemochromatosis. In these patients there is a continuous accumulation of hepatic iron as a result of increased intestinal absorption, and the increased load of iron results in hepatic malfunction.2728 One of the objectives of treatment with Sn-protoporphyrin in these patients was to determine if it was possible to increase the output of haeme and thus of its contained iron atom. In the present study we were able to show an increase in biliary haeme excretion in several of these patients after Snprotoporphyrin treatment, though the response was variable. The degree of increase was, however, similar to that seen in the primary biliary cirrhosis patients and also in normal volunteers. 3 It has recently been shown that increased biliary secretion of iron occurs during iron overload but also that the capacity of this excretory pathway is limited.20 Thus, whether it is feasible by administering haeme oxygenase inhibitors on a longterm basis to enhance biliary haeme and in this fashion iron excretion to a sufficient extent to induce a negative iron balance in haemochromatosis remains to be determined.
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